Background: Acne-like skin rash is a frequently occurring adverse event associated with drugs against the epidermal growth factor receptor. This randomized vehicle-controlled study investigated the addition of vitamin K1 cream to doxycycline in patients with metastatic colorectal cancer treated with cetuximab.
Introduction
Skin toxicities are experienced by the vast majority of patients treated with drugs directed against the epidermal growth factor receptor (EGFR). This is due to the fact that expression of the EGFR is not only observed on tumor cells but also in the keratinocytes, cells of eccrine and sebaceous glands and in the epithelium of hair [1] . Acneiform rash is by far the most frequent type of skin toxicity [2] . Skin rash may cause significant physical and psychosocial discomfort that can impair treatment adherence, dose intensity, and clinical outcome [3] . Tetracyclines such as doxycycline and skin care are recommended for the prophylaxis and treatment of EGFR inhibitor-mediated dermatologic toxicities [4] . This recommendation is based on the evidence from randomized trials [3, [5] [6] [7] [8] [9] [10] [11] [12] and a meta-analysis [13] . Despite of the prophylactic use of tetracyclines still a high percentage of patients suffers from grade 2 skin toxicities [3, 12] .
Vitamin K is a group of structurally similar fat-soluble vitamins. Vitamin K1 (phylloquinone, phytomenadione) is found in high amounts in green leafy vegetables. It is metabolized to vitamin K2 homologues (menaquinones), the active storage form in animals, via an intermediate (vitamin K3; menadione) [14] . Beier and coworkers showed activation of EGFR as well as downstream signaling in human keratinocytes exposed to menadione [15] . Likewise, short-term exposure to menadione caused EGFR activation and antagonized the EGFR inhibitory effect of cetuximab on human skin keratinocytes [16] . Topical use of vitamin K cream might therefore be suitable to reduce the incidence and/or mitigate the severity of acne-like skin rash.
Uncontrolled clinical trials suggested that vitamin K1 cream might be an effective prophylaxis against EGFR mediated skin rash [17] [18] [19] . For instance, Ocvirk and coworkers investigated the prophylactic use of vitamin K1 cream in patients with metastatic colorectal cancer (mCRC) receiving cetuximab. Among 143 patients only 17.8% had grade 2 and 0.7% grade 3 skin rash during a treatment period of 8 weeks [19] .
A major issue that complicates the conduct of studies in the field of skin rash is that conventional systems for grading skin reactions are subpar. The NCI CTCAE v. 4.02 criteria as the standard for grading adverse events focus on the percentage of the affected whole body surface. Proposals for more detailed grading systems have been made by the Multinational Association of Supportive Care in Cancer (EGFR Inhibitor Skin Toxicity Tool; MESTT) [20] , and by Wollenberg and coworkers (WoMo scoring system) [21] . The latter three-part system takes into consideration the involvement of whole body surface as well as skin involvement of the face, and describes the type of skin toxicity in a semi-quantitative manner.
The double-blind randomized, vehicle-controlled phase II EVITA trial sought to investigate the prophylactic use of vitamin K1 cream in addition to doxycycline in patients with mCRC receiving cetuximab-based first-line therapy. In addition to NCI CTCAE v.4.02 criteria, the WoMo grading system was used to optimize description of skin toxicity and to enable more thorough comparisons between the treatment arms.
Patients and methods
This randomized vehicle-controlled phase II study (clinical trials number NCT01345526) was an investigator-initiated clinical trial. The study was approved by the institutional review board of all participating centers and conducted according to Good Clinical Practice guidelines, the Declaration of Helsinki, and local laws.
Patients
The study population comprised patients with mCRC and (K)RAS wildtype (WT) tumors receiving first-line therapy with cetuximab and infusional 5-fluorouracil/irinotecan (FOLFIRI). Patients had to be willing and able to complete quality of life (QoL) forms and to keep patient diaries. WHO performance status had to be 1, and lower age limit was 18 years. Detailed inclusion criteria are provided as supplementary material, available at Annals of Oncology online.
Trial design and objectives
EVITA (Evaluation of VITAmin K) was a double-blind, vehiclecontrolled, randomized phase II trial evaluating the efficacy of combination therapy of doxycycline and vitamin K1 0.1% cream (Reconval K1 TM ) compared with doxycycline plus the respective vehicle (i.e. Reconval TM ) for the prevention of acne-like skin rash in mCRC patients with (K)RAS WT tumors receiving first-line cetuximab þ FOLFIRI.
The primary objective of this study was to investigate whether the prophylactic combination therapy with doxycycline plus vitamin K1 cream was superior to doxycycline plus the vehicle regarding the prevention of acne-like skin rash in terms of occurrence of grade 2 skin rash during an 8-week treatment period.
Secondary objectives comprised the comparison of skin rash between the two treatment arms according to the WoMO score, the evaluation of efficacy of first-line anticancer treatment [objective response rate according to RECIST 1.1 criteria, and progression-free survival (PFS)], general and skin-specific QoL (EORTC QLQ C30 and Dermatology Life Quality Index, DLQI), the evaluation of the effect of vitamin K1 on skin reactions other than acne-like rash, and the evaluation of safety (incident reporting only) and compliance with anticancer as well as prophylactic skin treatment.
Assessment and grading of skin rash and other skin reactions according to NCI CTCAE v. 4.02 criteria and the WoMo scoring was performed on a weekly basis for a total of 8 weeks (for further details see supplementary material, available at Annals of Oncology online).
Treatment regimens
Patients diagnosed with mCRC and having a (K)RAS WT tumor planned to be treated with cetuximab/FOLFIRI were randomized into two arms at a 1 : 1 ratio. Cetuximab was administered as per label (400 mg/m 2 loading dose and 250 mg/m 2 weekly thereafter). Starting on day 1 of the cetuximab/FOLFIRI regimen patients in arm A (experimental group) initiated doxycycline 100 mg b.i.d and applied vitamin K 0.1% cream (Reconval K1 TM ) twice daily on the face, chest, and back for a total of 8 weeks (skin treatment period). Patients in arm B received doxycycline and Reconval TM . In both arms, skin moisturizers were mandatory and sunscreen (SPF of at least 15) had to be applied for patients with sun exposure. Protocol specified skin treatment ended after 8 weeks.
Reconval K1 TM cream has been registered as a medical device class I on 28 February 2010 and is produced by Pharmadab (Ljubljana, Slovenia). Reconval K1
TM and the vehicle cream (Reconval TM ) were provided by Pharmadab.
Assessment and interpretation of skin toxicity and QoL
Skin toxicity was assessed and graded on a weekly basis using NCI CTCAE v.4.02 criteria [22] and WoMo criteria [21] . A key issue in the NCI CTC system regarding the grading of 'papulopustular rash' is that it relates to the percentage of the affected body surface area (BSA) and not to the severity of rash. It takes, however, into consideration psychological impact of rash, instrumental and self-care activities of daily living as well as superinfection (see supplementary Table S1 , available at Annals of Oncology online). The WoMo score is a tripartite scoring comprising the NCI CTCAE score regarding BSA (part A), the percentage of facial skin involvement (part B), and a semiquantitative description of five items of information on the nature of the rash considering the most severely affected region of the body (part C) including erythema intensity and distribution, papulation, pustulation, and scaling/crusts. The final score ranges from 0 to 100 (categorized 0-20 mild, 21-40 moderate, 41-100 severe; see supplementary Table S2 , available at Annals of Oncology online).
Patients filled in the EORTC QoL questionnaire C30 (QLQ C30) and DLQI [23] questionnaire at baseline (week 0), weeks 2, 4, 6, and 8 and at week 12. Details on QoL assessment are provided in the supplementary material, available at Annals of Oncology.
Statistical methods
Following the results of the STEPP trial [3] it was assumed that the percentage of patients with skin rash grade 2 (NCI CTC AE v.4.02) during the 8 weeks skin treatment period was 30%. The sample size was calculated such that a difference of 20% points (e.g. 10% in the experimental arm with vitamin K 0.1% cream and 30% in the standard arm B with vehicle) could be detected with 80% power at a two-sided significance level of 0.05 using a stratified Cochran-Mantel Haenszel test. The randomization was stratified by gender. Based on these assumptions, the resulting sample size was 124 patients (62 per arm). Further details on statistical methods are provided as supplementary material, available at Annals of Oncology online.
Results

Patient characteristics
Between June 2011 and May 2015, 127 patients were randomized by 16 centers. One patient did not start treatment. Thus, 126 patients were available for the analysis (Figure 1 ). Patient characteristics are provided in Table 1 .
Primary end point: incidence of acne-like rash according to NCI CTCAE criteria
The primary end point for this study was the incidence of acnelike rash (grades 2-4) during the 8-week treatment with vitamin K/vehicle cream. For a total of 86 out of 126 patients (68.3%), acne-like skin rash grades 2-4 was documented: 42 (63.6%) in the vehicle group and 44 (73.3%) in the vitamin K group. The difference between the treatment groups was not statistically significant (P ¼ 0.28). The stratified odds ratio (OR) for the vitamin K treatment group relative to the vehicle group was 1.57 [95% confidence interval (95% CI): 0.70-3.54]. The treatment effect of vitamin K on acne-like skin rash grades 2-4 remained nonsignificant in the multiple logistic regression analysis (OR 1.76; 95% CI: 0.75-4.14; P ¼ 0.20), if adjusted by gender, which was the only significant covariable [showing a reduced risk in females versus males (OR 0.15; 95% CI: 0.06-0.36; P < 0.01)].
Comparison of skin toxicity between the treatment arms according to WoMo criteria and efficacy of vitamin K in terms of other skin reactions
The mean values for the WoMo score during the skin treatment period were 18.0 [standard deviation (SD) 13 .05] for the vehicle and 18.0 (SD 13.37) for vitamin K. Similarly, no differences were noticed with respect to the WoMo score subcategories (A, B, and C). Five percent (vitamin K arm) and 6.1% (vehicle) of the patients were classified as having severe WoMo score (above 40 points) over time, respectively.
The results of the median WoMo score 'per week' are depicted in supplementary Tables S3 (overall WoMo score, i.e. including parts A, B, and C) and S4 (describing the severity of the rash), available at Annals of Oncology online. The numerical differences of WoMo scores between the WoMo scores in the two treatment arms increase over time in favor of the vitamin K cream due to more favorable results of WoMo score part C (as a sign for less severe rash in the most severely affected skin areas). Likewise, an exploratory analysis taking into account only patients with values for WoMo score term C in week 8 at the end of treatment (n ¼ 87 patients) suggests an increasing benefit of vitamin K cream administration over time (Figure 2) . The percentage of patients developing other types of skin toxicity of NCI CTCAE grade 2 (including dry or wet eczema, pulpitis of finger, telangiectasia, hyperpigmentation, hair changes, paronychia, and pyogenic granuloma) were not different between treatment groups (data not shown). However, a significant reduction in the rate of fissures was noticed in favor of patients treated in the vitamin K arm (14% versus 3%, OR 0.22; 95% CI: 0.05-1.06).
Antitumor activity
All patients had measurable disease at baseline. Tumor remissions were achieved in 31 (47.0%) patients in the vehicle group and in 30 (50.3%) in the vitamin K group (stratified OR 1.13; 95% CI: 0.56-2.25). With regard to the multivariate analysis only liver metastases at baseline had a statistically negative impact on tumor remission (stratified OR 0.36; 95% CI: 0.16-0.78).
Median PFS was 7.44 months in the vehicle group and 8.75 months in the vitamin K arm (stratified Hazard ratio (HR) 0.91; 95% CI: 0.46-1.81). In multivariate Cox's regression analysis only the covariate 'right-sided primary tumor' showed a statistically significant (negative) effect on PFS (HR 0.45, 95% CI: 0.23-0.88).
Compliance with skin treatment, extent of exposure to chemotherapy and incident reporting Supplementary Table S5 , available at Annals of Oncology online, provides an overview of treatment duration, cumulative doses administered with regard to the different components of anticancer treatment as well as of the adherence to the prophylactic skin treatment (i.e. doxycycline and vitamin K1/vehicle cream) during the skin treatment period (i.e. the first 8 weeks of treatment). In summary, no differences in treatment duration or doses administered were noticed between treatment arms for both, anticancer treatment and skin treatment.
No incidents were reported with regard to the medical devices Reconval TM and Reconval K1 TM .
QoL analysis
The compliance regarding the QoL questionnaires was good. About 122 (97%) patients filled in the DLQI questionnaire at baseline, n ¼ 115 (91%) after 2 weeks, n ¼ 99 (79%) after 4 weeks, n ¼ 95 (75%) after 6 weeks, and n ¼ 80 (63%) at the end of the skin treatment period after 8 weeks. For 92.4% of the patients in the vehicle group and 88.3% of the patients in the vitamin K treatment group, DQLI at baseline indicated no effect of skin problems at all on patient's life. DLQI scores worsened in both treatment arms over time, but no striking differences were noticed (supplementary Table S6 , available at Annals of Oncology online).
Median global health status at baseline was 66.7 in both treatment arms and did not change over the 12 weeks observation period. Likewise, values in functional and symptom scales did not differ over time between treatment arms (data not shown).
Discussion
The current trial sought to decrease the incidence of cetuximabrelated skin rash grades 2-4 using vitamin K1 cream in addition to a standard prophylaxis with doxycycline in patients with mCRC. However, the incidence of skin rash grades 2-4 was comparable in both arms and the primary end point was not met.
At the beginning of the study, we faced two methodological dilemmas. Firstly, NCI CTCAE criteria were regarded as a standard for the classification of acne-like skin rash and were used as end points in clinical trials. NCI CTCAE criteria, however, focus mainly on the percentage of the affected body surface. The 'severity' of rash affecting a circumscribed skin area (e.g. the face) is indescribable by NCI CTCAE criteria. Secondly, the sample size calculation of the EVITA trial was based on data from the STEPP trial which used a modified earlier version of the NCI CTCAE criteria (version 3.0) [3] . Thus, an alternative and more thorough grading system (WoMo) was used in the EVITA trial as a secondary end point. It was anticipated that WoMo would allow a more detailed and sensitive comparison than the NCI CTCAE criteria, regardless of the CTCAE results.
Much diligence was applied to correctly document and grade affections of the skin. All physicians were trained by the principal investigator to correctly use the NCI CTCAE and WoMo scores. Moreover, skin toxicity was scored on a weekly basis for 8 weeks. Finally, patients filled in a patient's diary to document the compliance with both, use of the cream and doxycyclines.
A main finding of the WoMo scoring analysis is that the severity of rash (as assessed with WoMo part C) was less in the experimental arm. This effect becomes visible at week 5 and increased over time thereafter. The relative reduction in the median WoMo score part C per week by applying vitamin K1 versus the vehicle is continuously increasing between weeks 5 and 8 from 29% to 50%. Four weeks after the end of the skin treatment period, the median WoMo score part C is still lower in patients treated in the experimental arm. However, this observation is based on one-third of the study patients only. Another hint that the vitamin K cream may be efficacious in mitigating skin toxicity is the significantly lower incidence of fissures in the experimental arm. Note that patients were asked to use cream twice daily which might be an explanation why the fissure rate on finger tips was lower.
QoL measures as determined with EORTC QLQ C30 and DLQI were not different between treatment groups. When EVITA was started, a dedicated tool to assess skin-related QoL was not available for patients undergoing treatment with EGFR inhibitors. Thus, it is possible that differences in QoL were not captured by these questionnaires. Meanwhile, the FACT EGFRI 18 has been developed as a tool to estimate skin-related QoL for patients undergoing treatment with anti-EGFR drugs [24] .
With regard to secondary end points, it was shown that compliance with the prophylactic skin treatment was comparable between both arms. Likewise, the doses and treatment duration was identical in both arms for all antineoplastic drugs administered. Accordingly, the response rates and the PFS results were not different indicating that no systemic vitamin K effect could be observed impacting on patients' outcome.
In all, the EVITA trial is among the first trials to use a more thorough grading system as an end point for the description of skin reactions relating to anti-EGFR drugs. Vitamin K1 cream was shown to decrease the severity of skin rash according to the WoMo score while no effect was seen with respect to the reduction of the percentage of the affected skin surface. Moreover, fewer fissures were reported during the skin treatment period suggesting a potential effect of vitamin K1 cream. However, the trial is formally negative and vitamin K1 cream cannot be claimed a standard of care for the prevention of acne-like skin rash. Nevertheless, in view of the lower severity of rash observed with vitamin K, we believe that vitamin K-containing skin moisturizers should be investigated further. The WoMo score may help to better estimate skin rash important for both, the development of new antitumor agents and novel treatments against skin rash in clinical trials. We propose to implement this scoring tool in future studies dedicated to investigate acne-like skin rash.
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